ReviewAJNR. American journal of neuroradiology2019
Non-Contrast-Enhancing Tumor: A New Frontier in Glioblastoma Research.
Review in AJNR. American journal of neuroradiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity.Journal of neuro-oncology · 2023Pooled it
- Clinical outcomes as a function of the number of samples taken during stereotactic needle biopsies: a meta-analysis.Journal of neuro-oncology · 2021Pooled it
- Predicting glioblastoma progression using MR diffusion tensor imaging: A systematic review.Journal of neuroimaging : official journal of the American Society of NeuroimagingPooled it
- Localized blood-brain barrier opening in infiltrating gliomas with MRI-guided acoustic emissions-controlled focused ultrasound.Proceedings of the National Academy of Sciences of the United States of America · 2021Trial
- PREDICT-GBM: A multicenter platform advancing personalized glioblastoma radiotherapy planning.NPJ digital medicine · 2026Article
- Multi-sampling allows intra-tumoral heterogeneity querying and vulnerability profiling in glioblastoma.Neuro-oncology · 2026Article
- Hypoxia-targeted BOLD MRI signal heterogeneity as a complementary metric for glioblastoma characterization: a pilot study.Journal of neuro-oncology · 2026Article
- Article
- Spatially identifying regions of tumor recurrence in patients with suspected recurrent glioma using physiologic MRI and machine learning.NPJ digital medicine · 2026Article
- Spatial-temporal recurrence patterns of grade 4 glioma using deep learning integrated multiparametric MRI and molecular pathology.NPJ precision oncology · 2026Article
- Automated delineation of putative non-contrast-enhancing tumor in glioblastoma: Prognostic insights.Neuro-oncology · 2026Article
- Management of Adult Patients With Isocitrate Dehydrogenase-Mutant Gliomas in Australia: An Expert Position Statement From the Cooperative Trials Group for Neuro-Oncology.Asia-Pacific journal of clinical oncology · 2026Review
- Mapping Intracellular Volume Fraction With Susceptibility Source Decomposition as a Marker for Tissue Cellularity.Journal of magnetic resonance imaging : JMRI · 2026Article
- Magnetic resonance imaging features differentiate histologic and molecular subtypes of glioblastoma IDH-Wild type CNS WHO grade 4.Journal of neuro-oncology · 2026Article
- Does pattern of 5-aminolevulinic acid (5-ALA) residual intra-operatively predict worse outcome in glioblastoma?Brain & spine · 2026Article
- Radiomics Analysis of Non-Enhancing Lesions After Bevacizumab Administration in Recurrent Glioblastoma.Bioengineering (Basel, Switzerland) · 2025Article
- Radiomics-based quantification of tumor infiltration in the non-enhancing peritumoral region on postoperative MRI is associated with survival in glioblastoma.Scientific reports · 2025Article
- Machine learning-based integration of dosiomics and pre-radiotherapy multimodal MRI radiomics for survival stratification in patients with glioblastoma multiforme.Radiation oncology (London, England) · 2025Article
- MRI-based prediction of DNA methylation grade in IDH-mutant astrocytomas using qualitative imaging features and tumor volumetrics.Neuroradiology · 2025Article
- Magnetic susceptibility properties of tumor-associated cells imaged by MRI reveal glioblastoma infiltration in the edema region.Communications medicine · 2025Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a growing understanding of the prognostic importance of non-contrast-enhancing tumor in glioblastoma, and recent attempts at more aggressive management of this component using neurosurgical resection and radiosurgery have been shown to prolong survival. Optimizing these therapeutic strategies requires an understanding of the features that can distinguish non-contrast-enhancing tumor from other processes, in particular vasogenic edema; however, the limited and heterogeneous manner in which it has been defined in the literature limits clinical translation. This review covers pertinent literature on our growing understanding of non-contrast-enhancing tumor and focuses on key conventional MR imaging features for improving its delineation. Such features include subtle differences in the degree of FLAIR hyperintensity, gray matter involvement, and focal mass effect. Improved delineation of tumor from edema will facilitate more aggressive management of this component and potentially realize associated survival benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.